<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180307</url>
  </required_header>
  <id_info>
    <org_study_id>OTL-2016-OTL38-006</org_study_id>
    <nct_id>NCT03180307</nct_id>
  </id_info>
  <brief_title>OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</brief_title>
  <official_title>A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On Target Laboratories, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>On Target Laboratories, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in
      patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to
      undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 3 study is to confirm the efficacy of OTL38 in combination with fluorescent light
      to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by
      palpation and visualization under normal light in patients with FR+ ovarian cancer scheduled
      to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer
      surgery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy patient level</measure>
    <time_frame>30 days</time_frame>
    <description>• Proportion of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient false positive rate</measure>
    <time_frame>30 days</time_frame>
    <description>• False Positive Rate at the patient level (FPRp) will be a major secondary efficacy endpoint and is defined as the proportion of folate positive ovarian cancer patients in whom all lesions, without regard to evaluable lesion status, detected by fluorescent light only, are histologically negative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>no fluorescent imaging</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patient injected with OTL38, but does not undergo fluorescent imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient injected with OTL38 and undergoes near infrared imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTL38</intervention_name>
    <description>0.025 mg/kg of OTL38 in 250ml D5W infused intravenously over 60 minutes</description>
    <arm_group_label>no fluorescent imaging</arm_group_label>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <other_name>OTL38 for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>near infrared imaging</intervention_name>
    <description>Infrared imaging used to excite OTL38 for fluorecence</description>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <other_name>Near IR imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Female patients 18 years of age and older 2. Have a primary diagnosis, or at high
             clinical suspicion, of primary ovarian cancer (of epithelial type), planned for
             primary surgical cytoreduction, interval debulking, or have recurrent ovarian cancer
             surgery, and:

               -  Who are scheduled to undergo laparotomy for the debulking surgery OR

               -  Who are scheduled to undergo laparoscopy and pre-authorized to undergo laparotomy
                  for the debulking surgery if cancer is detected on the laparoscopy 3. A negative
                  serum pregnancy test at Screening followed by a negative urine pregnancy test on
                  the day of surgery or day of admission for female patients of childbearing
                  potential 4. Female patients of childbearing potential or less than 2 years
                  postmenopausal agree to use an acceptable form of contraception from the time of
                  signing informed consent until 30 days after study completion 5. Ability to
                  understand the requirements of the study, provide written informed consent for
                  participation in the study and authorization of use and disclosure of protected
                  health information, and agree to abide by the study restrictions and to return
                  for the required assessments

        Exclusion Criteria:

          -  1. Previous exposure to OTL38 2. Known FR-negative ovarian cancer 3. Planned surgical
             debulking via laparoscopy or robotic surgery, with no intent of laparotomy.

             4. Patients with known ovarian cancer miliary disease prior to surgery 5. Any medical
             condition that, in the opinion of the investigators, could potentially jeopardize the
             safety of the patient 6. History of anaphylactic reactions 7. History of allergy to
             any of the components of OTL38, including folic acid 8. Pregnancy or positive
             pregnancy test 9. Clinically significant abnormalities on electrocardiogram (ECG) 10.
             Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule 11.
             Impaired renal function defined as eGFR&lt; 50 mL/min/1.73m2 12. Impaired liver function
             defined as values &gt; 3x the upper limit of normal (ULN) for alanine aminotransferase
             (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total
             bilirubin.

             13. Known Stage IV ovarian cancer with brain metastases 14. Received an
             investigational agent in another clinical trial within 30 days prior to surgery 15.
             Known sensitivity to fluorescent light
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janos Tanyi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Biro, MBA</last_name>
    <phone>2165333082</phone>
    <email>tgboif@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aaron Blouin, BA</last_name>
    <phone>215-908-5866</phone>
    <email>Ablouin@ontargetlabs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of CA at Irvine Chao Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Randall, MD</last_name>
      <phone>714-456-7971</phone>
      <email>lrandall@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Randall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wenham, MD</last_name>
      <phone>813-745-4933</phone>
    </contact>
    <investigator>
      <last_name>Robert Wenham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maureen Lemens, MD</last_name>
      <phone>507-293-1487</phone>
      <email>Lemens.Maureen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Carrie Langstraat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Streifthau, BSN, RN</last_name>
      <email>Allison.Streifthau@ketteringhealth.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Reid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janos L Tanyi, MD, PhD</last_name>
      <phone>267-279-7255</phone>
    </contact>
    <investigator>
      <last_name>Janos Tanyi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

